Achlys human cardiomyocytes expressing
human hERG Kv11.1 potassium ion channel

Key Benefits

Currently available hERG expressing cell lines in the market are not capable of mirroring the full physiological response of a cardiac cell, let alone the heart, or the body. Thus, the predictive power of the hERG assay for the torsadogenicity of a specific compound is far from ideal and the quest for more predictive novel test systems is much needed.

For this reason, we have developed a novel human ventricular cardiomyocyte cell line for assessing the cardiac liabilities of compounds, within a more native environment of the channels.

Key Benefits

  • Cell line derived from adult human ventricular cardiomyocytes.
  • Able to measure hERG blocking along with general cardiotoxicity activity of drug candidates
  • Can be run over a broader range of temperatures, ranging from room temperature to physiological temperatures (37° C).
  • Offers better alternative to commonly used HEK & CHO cell-lines expressing hERG.
  • System mirrors the biochemical and physiological response of a cardiac cell.
  • Stably expressing high levels of functional hERG channels.
  • Low variance in test currents.
  • More stable and reproducible than stem cell-derived cardiomyocytes without associated ethical issues.